2.90MMarket Cap-86P/E (TTM)
1.3397High1.2900Low82.19KVolume1.3100Open1.3300Pre Close106.87KTurnover5.24%Turnover RatioLossP/E (Static)2.25MShares19.410052wk High0.53P/B2.02MFloat Cap1.225052wk Low--Dividend TTM1.57MShs Float800.0000Historical High--Div YieldTTM3.74%Amplitude1.2250Historical Low1.3000Avg Price1Lot Size
NuCana Stock Forum
550% CTB loading 1.5 too 1.6
EDINBURGH, United Kingdom, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors (Module 1) and in combination with docetaxel for patients with lun...
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
NuCana announced initial data from its Phase 1b/2 study of NUC-3373 in combination therapies. In Module 1, combining NUC-3373 with pembrolizumab showed promising results in 12 advanced solid tumor patients, achieving a 22% objective response rate and 67% disease control rate. Notable cases included a bladder cancer patient achieving 100% target ...
No comment yet